These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25743274)

  • 1. Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.
    Timmers L; Boons CC; Moes-Ten Hove J; Smit EF; van de Ven PM; Aerts JG; Swart EL; Boven E; Hugtenburg JG
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1481-91. PubMed ID: 25743274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of erlotinib in daily practice: a study on adherence and patients' experiences.
    Timmers L; Boons CC; Mangnus D; Moes JE; Swart EL; Boven E; Smit EF; Hugtenburg JG
    BMC Cancer; 2011 Jul; 11():284. PubMed ID: 21722354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
    J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
    Gebbia V; Bellavia M; Banna GL; Russo P; Ferraù F; Tralongo P; Borsellino N
    Clin Lung Cancer; 2013 Jul; 14(4):390-8. PubMed ID: 23313173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
    Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
    Stepanski EJ; Houts AC; Schwartzberg LS; Walker MS; Reyes CM; Blakely J
    Clin Lung Cancer; 2009 Nov; 10(6):426-32. PubMed ID: 19900861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
    J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
    N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
    J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemolytic anemia under erlotinib treatment].
    Sakhri L; Mennecier B; Quoix A
    Rev Pneumol Clin; 2013 Dec; 69(6):345-50. PubMed ID: 24183296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
    Casal Rubio J; Fírvida-Pérez JL; Lázaro-Quintela M; Barón-Duarte FJ; Alonso-Jáudenes G; Santomé L; Afonso-Afonso FJ; Amenedo M; Huidobro G; Campos-Balea B; López-Vázquez MD; Vázquez S
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):451-7. PubMed ID: 24352251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
    Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
    Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
    Boyer M; Horwood K; Pavlakis N; De Souza P; Millward M; Stein B; Johnston M; Abell F; Rischin D
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors.
    Rosentreter J; Alt J; Fried M; Chakupurakal G; Stratmann J; Krämer I
    J Oncol Pharm Pract; 2021 Jul; 27(5):1147-1158. PubMed ID: 32746691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.